Refine search

Search Application

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term:

Results 1 - 8 of 8
EC Number
Application
Commentary
Reference
drug development
activated factor XI inhibition as a viable method to increase the ratio of benefit to risk in an antithrombotic drug
medicine
anti-thrombosis therapy
medicine
antithrombosis therapy
medicine
blood coagulation
medicine
diagnosis of FXI deficiency may be considered in patients with delayed postoperative bleeding and prolonged activated partial thromboplastin time, especially in a demographically high-risk population, such as Ashkenazi Jews. Women with severe FXI deficiency and prolonged activated partial thromboplastin time can be managed with fresh frozen plasma transfusion before neuraxial anesthesia
medicine
the enzyme may be a suitable target for the development of an antithrombotic therapy
medicine
therapeutically targeting FXI may offer a strategy for preventing or treating arterial thrombosis that is not associated with the high rate of hemorrhage that accompanies many currently used anticoagulants. Pharmacological FXI inhibitors may be beneficial in septic disease
medicine
treatment options for FXI-deficient patients include virus-inactivated fresh frozen plasma, plasma-derived FXI concentrates, and activated recombinant FVII. Potential role of desmopressin for either treatment of bleeding episodes or the prevention of postoperative bleeding in patients with milder FXI defects. A single desmopressin infusion is sufficient to provide an efficient perioperative hemostasis
Results 1 - 8 of 8